Business
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Company to host conference call today at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":"Company to host conference call today at 8:00 a.m. EST\nSOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.\n “2019 was a year of strategic prioritization and significant advancement of our T-cell immunotherapy programs,” said Pascal Touchon, President and Chief Executive Officer of Atara. “In 2020 we plan to deliver on key milestones across our pipeline and further establish Atara as a leader in off-the-shelf, allogeneic T-cell immunotherapies through our innovative EBV T-cell platform, next-generation CAR T technologies and state-of-the-art manufacturing capabilities. This work underpins our mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence.” Recent Highlights and Anticipated Upcoming Milestones Tab-cel® (tabelecleucel) Atara continues to progress tab-cel® Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) Atara remains on track to initiate a tab-cel® biologics license application (BLA) submission for patients with EBV+ PTLD in the second half of 2020Atara plans to discuss the totality of tab-cel® results with the U.S. Food and Drug Administration (FDA) in a pre-BLA meeting prior to initiating the BLA submissionIn the U.S. and Australia, 38 sites are available for enrollment and the Company is preparing to open additional sites in the U.S., Canada and EuropeAtara submitted clinical trial applications (CTAs) to several European countries in November and December 2019 to enable the opening of EU clinical sites in 2020. The Company’s CTAs in the United Kingdom, Spain and Austria were recently approved Atara recently submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMA) Following EMA approval of the PIP, Atara plans to submit a tab-cel® EU marketing authorization application for patients with EBV+ PTLD in 2021 Atara continues to see strong tab-cel® investigator, physician and patient interest and, for cases in w...